Amedica Announces Pricing of $11 Million Public Offering

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amedica Announces Pricing of $11 Million Public Offering

SALT LAKE CITY, UT--(Marketwired - Jul 5, 2016) -  Amedica Corporation ( NASDAQ : AMDA ), a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of units for gross proceeds of $11 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Amedica.

The offering is comprised of Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and one five-year warrant (each, a "warrant") to purchase one share of common stock with an exercise price of $1.00 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock which is convertible into 1,000 shares of common stock and 1,000 warrants. The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed priced and do not contain any variable pricing features nor any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to extent dividends are also paid on the common stock), liquidation preference or other preferences over common stock. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about July 8, 2016, subject to the satisfaction or waiver of customary closing conditions.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. ( NYSE MKT : LTS ), and Maxim Group LLC are acting as joint book-running managers in connection with the offering.

A total of 3,608,000 shares of common stock, 7,392 shares of preferred stock convertible into 7,392,000 shares of common stock, and warrants to purchase 11,000,000 shares of common stock will be issued in the offering.

In addition, Amedica has granted the underwriters a 45-day option to purchase up to 1,650,000 additional shares of common stock and/or additional warrants to purchase up to 1,650,000 shares of common stock solely to cover over-allotments, if any, at the public offering price per share and warrant less the underwriting discounts and commissions.

The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-211520), which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 1, 2016.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering will be filed by Amedica with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 570 Lexington Avenue, 11th Floor, New York, New York 10022, by calling (212) 409-2000 or from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174 by calling (212) 895-3745.

About Amedica Corporation Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company's products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit  www.amedica.com .

Forward-Looking Statements This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements and similar statements are subject to risks and uncertainties such as changes in the market impacting the ability of the Company to close the expected offering. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts: Mike Houston VP, Commercialization 801-839-3534 IR@amedica.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading